RESOURCES

PEOPLE

Mohammad Azab will take up the newly created position of vice president, clinical research and medical affairs of QLT PhotoTherapeutics (Vancouver, BC, Canada). Dr. Azab comes to QLT from Zeneca Pharmaceuticals, where he was responsible for clinical development of oncology and gynecology drugs.

ImmunoGen (Cambridge, MA) announced the following promotions of the senior management team: Walter A. Blättler has been promoted to executive vice president, science and technology, from his position as senior vice president, research and development; Frank J. Pocher has been promoted to executive vice president, operations, from his former position as vice president and CFO; John M. Lambert, formerly vice president of research, has been promoted to vice president of R&D; and Kathleeen A. Carroll, previously corporate controller, has been named vice president, finance and administration.

Enzon, Inc. (Piscataway, NJ) has announced the appointment of Rolf A. Classon to its board of directors. Mr. Classon is currently president of Bayer Diagnostics, part of the Bayer group, and executive vice president of Bayer Corporation. From 1990-1991, he served as president and chief operating officer of Pharmacia Biosystems AB.

Behring Diagnostics GmbH (Frankfurt, Germany) has announced that Gilles de Robert has been named to the position of general manager of Behring Diagnostics SA in France, replacing Andre Chalandon, who is leaving to pursue other endeavors. Mr. de Robert was most recently the managing director of Saulnier Duval ECC (Paris).

Chiron Corp. (Emeryville, CA) has announced the resignation of Dino Dina as president of Chiron Vaccines. Chiron has named Magnus Lundberg to replace Dr. Dina. Lundberg also will continue as president of Chiron Therapeutics. He joined Chiron in August 1996 from Pharmacia & Upjohn, where he was most recently head of metabolic diseases.

Donald Kennedy has been elected to the board of directors of Arris Pharmaceutical Corp. (S. San Francisco, CA). Dr. Kennedy was president of Stanford University from 1980 to 1992, and was also commissioner of the US Food and Drug Administration.

Graham S. May has been named vice president, medical affairs, of Cytogen (Princeton, NJ). Dr. May's most recent position was as a

principal in the Global Health Care Practice of Gemini Consulting. Prior to Gemini, Dr. May spent 10 years with Kabi Pharmacia, Inc., the US subsidiary of Kabi Pharmacia, Sweden.



MitoKor (San Diego, CA) has announced that Walter H. Moos has been named chairman and chief executive officer. Dr. Moos was most recently corporate vice president and vice president of R&D at

Chiron Technologies.

Receptagen Ltd. (Edmonds, WA) has announced that A. Charles Morgan has resigned from his position as president of Receptagen Corp., chief technical officer of Receptagen Ltd., as well as his board position, effective immediately. Dr. Morgan, a cofounder, has been at Receptagen with the company since its incorporation in June 1992.

Ergo Science Corp. (Boston, MA) has announced that Richard A. Paul has been appointed senior vice president of medical affairs to spearhead its clinical research efforts. Dr. Paul most recently served as vice president of clinical research at Schering-Plough Healthcare Products. Prior to this, he was executive director of clinical research at Sandoz Pharmaceuticals. Ergo has also announced that W. Leigh Thompson has been elected to its board of directors. In 1995, Dr. Thompson retired as the chief science officer of Eli Lilly and Company.

Timothy J. Rink has been named to the board of directors of Alanex Corp. (San Diego, CA). Dr. Rink is a founder of Aurora Biosciences, and from 1990 to 1995 was president and chief technical officer of Amylin Pharmaceuticals.

Pharmaceuticals' Incyte (Palo Alto, CA) board of directors have named Randy W. Scott president and chief scientific officer. Dr. Scott was previously executive vice president and CSO. Roy A. Whitfield, formerly president and CEO, will continue in his role as CEO. The following have also been promoted to vice president: Kent Davidson, vice president, marketing; Richard D. vice president, Goold,

research genomics; Marian N. Marra, vice president, medical and technology ventures; and Lisa L. Peterson, vice president, business development.

Anergen (Redwood City, CA) has announced the appointment of Michael Shulman as vice president, medical affairs, and David Mitchell as associate director of regulatory affairs. Previously, Dr. Shulman was in the medical department at Sangstat, Syntex, and Sandoz. Mr. Mitchell joins Anergen from BRI International.



Serologicals Corp. (Atlanta, GA) has announced the appointment of Toby Simon as vice president of medical and scientific affairs. Dr. Simon was previously the president of Blood Systems Foun-

dation. He has also held the position of president of America's Blood Centers and the American Association of Blood Banks.

Henri A. Termeer has been elected to Diacrin's (Charlestown, MA) board of directors. Mr. Termeer is currently chief executive officer and chairman of Genzyme. He is also chairman of the Biotechnology Industry Organization (BIO) and a board member of the Massachusetts High Technology Council.



Wayne Yetter has been named president and CEO of Novartis Pharmaceuticals

Corp. USA (East Hanover, NJ). Since 1991, Mr. Yetter has held the positions of general manager, and

then president and CEO, of Astra Merck Inc.





Biotechnologie

KRAEBER GMBH & CO
PHARMAZEUTISCHE ROHSTOFFE

RENGELSO 2014 Newton: 0x and galactication of fax 44504041012 2014

Rengelso do 2014 Newton: 0x do and galactication of fax 44504041012 2014

Rengelso do 2014 Newton: 0x do and control control 2014 2014

Rengelso do 2014 Newton: 0x do and control 2014 2014

Rengelso do 2014 Newton: 0x do and control 2014 2014

Rengelso do 2014 Newton: 0x do and control 2014 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014 Newton: 0x do and control 2014

Rengelso do 2014

Rengelso do 2014

Rengelso do 2014

Rengelso do 2

We are main producer of sera, plasma and other selected blood derivatives for tissue culture, microbiology and diagnostics of the local animals in Europe for Biotechnology.

INTERESTED ?
Please call for our catalogue and offers.

Kraeber GmbH & Co, Biotechnology Division Hafenstrasse 32, D-22880 Wedel, Tf.+49-4103-820 01 Fax +49-4103-897 69

Kraeber (UK) Ltd The Street, Saxon Street, nr. Newmarket CD8 9RU Tf.+44-1638-731 297 fax +44-1638-731 291